Table 1.
Patient Characteristics at Presentation
| Characteristics | Radiotherapy+Pyrotinib (n=66) | Pyrotinib (n=26) | P | |
|---|---|---|---|---|
| Age (year) | ≤52 | 34 (51.5%) | 15 (57.7%) | 0.593 |
| >52 | 32 (48.5%) | 11 (42.3%) | ||
| HR status | HR negative | 37 (56.1%) | 17 (65.4%) | 0.413 |
| HR positive | 29 (43.9%) | 9 (34.6%) | ||
| T stage | T1 | 17 (25.8%) | 3 (11.5%) | 0.377 |
| T2 | 23 (34.8%) | 12 (46.2%) | ||
| T3 | 22 (33.3%) | 9 (34.6%) | ||
| T4 | 4 (6.1%) | 2 (7.7%) | ||
| N stage | N0 | 4 (6.1%) | 1 (3.8%) | 0.166 |
| N1 | 21 (31.8%) | 4 (15.4%) | ||
| N2 | 17 (25.8%) | 9 (34.6%) | ||
| N3 | 24 (36.4%) | 12 (46.2%) | ||
| ECOG | 0 | 19 (28.8%) | 6 (23.1%) | 0.321 |
| 1 | 36 (54.5%) | 12 (46.2%) | ||
| 2 | 11 (16.7%) | 8 (30.8%) | ||
| Metastatic sites | Lung | 20 (30.3%) | 11 (42.3%) | 0.273 |
| Bone | 30 (45.5%) | 9 (34.6%) | 0.343 | |
| Hepatic | 18 (27.3%) | 9 (34.6%) | 0.486 | |
| No. of brain metastatic | ≤3 | 33 (50%) | 11 (42.3%) | 0.506 |
| >3 | 33 (50%) | 15 (57.7%) | ||
| Size of brain metastatic | ≤2cm | 24 (36.4%) | 15 (57.7%) | 0.062 |
| >2cm | 42 (63.6%) | 11 (42.3%) | ||
| PriorHER2-targeted therapy | Trastuzumab | 43 (65.2%) | 16 (61.5%) | 0.867 |
| Trastuzumab+Pertuzumab | 12 (18.2%) | 6 (23.1%) | ||
| Others | 11 (16.6%) | 4 (15.4%) | ||
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HR, Hormone-receptor.